Proceeds from website advertising help sustain Lab Tests Online. AACC is a not-for-profit organization and does not endorse non-AACC products and services.

Multiple Myeloma

Print this article
Share this page:

Tests and Staging

The goals of testing for multiple myeloma are to diagnose the condition, determine its severity and spread, monitor its progress, detect complications as they arise, and monitor the effectiveness of treatment.

There is no one single test that can diagnose multiple myeloma. Typically, the disease is diagnosed using a combination of a person's signs and symptoms, medical history, physical examination, laboratory tests, and/or imaging tests.

Laboratory tests
Multiple myeloma may first be detected during routine wellness testing. It may be suspected when a person has:

Findings such as these may raise suspicions but are not diagnostic as similar results may be seen with a variety of other conditions. Rather, they indicate the need for further testing.

Tests used as a follow-up to abnormal routine tests and to help diagnose the disease may include one or more of the following:

  • Protein and immunofixation electrophoresis. These tests are used to help diagnose and monitor multiple myeloma. Protein electrophoresis separates the proteins in a blood or urine sample into several groups based on their electrical charge and size. In most people with multiple myeloma, large amounts of an abnormal immunoglobulin protein (M-protein) may show up as a large peak on the electrophoresis scan, also known as an M spike. The amount of normal immunoglobulins in the sample may be visibly decreased as well. Usually, both a blood and a urine sample will be tested to detect free light chains and intact immunoglobulins. Immunofixation electrophoresis is done to identify the specific type of protein that is being produced by the malignant plasma cells. The amount of protein produced may vary throughout the course of the disease, but the type will remain the same.
  • Urine free light chains (Bence Jones protein). These can be detected in the urine of some people with multiple myeloma. The sample tested is usually a 24-hour urine (a collection of all urine voided over a 24-hour period) because the total amount of free light chains in 24 hours is related to the amount of tumor that is present. Either the kappa or lambda light chains (but not both in the same person) may be measured to help diagnose multiple myeloma and monitor the effectiveness of treatment.
  • Serum free light chains (SFLC). This test measures the amount of free light chains in the blood. Even in normal circumstances (and for unknown reasons), plasma cells produce an excess of light chains compared to heavy chains, and there is usually a small amount of light chains that do not become incorporated into intact immunoglobulins. These remain as free light chains and are released into the bloodstream. Most people with multiple myeloma produce increased amounts of either kappa or lambda free light chains, which can be measured in blood. Consequently, the ratio of kappa to lambda light chains is abnormal and is a sensitive indicator for this disease. This test is used to monitor progression and/or treatment.
  • Quantitative immunoglobulins. Each of these tests measures amounts of a different type of immunoglobulin, or antibody, in the blood. The multiple myeloma protein may be an IgG, IgA or, rarely, an IgD or IgE immunoglobulin. People with a monoclonal IgM immunoglobulin may have a related but different disease (Waldenstrom macroglobulinemia). Tests for IgG, IgA, and IgM may be ordered to help diagnose multiple myeloma and to monitor the course of the disease and its effect on the production of normal immunoglobulins. Note that the test does not differentiate abnormal immunoglobulin produced by myeloma cells and the non-tumor immunoglobulin of the same type produced by normal plasma cells.
  • Serum immunoglobulin heavy chain/light chain. These tests can identify separately the different light chain types of each immunoglobulin class, including IgG-kappa, IgG-lambda, IgA-kappa, IgA-lambda, IgM-kappa, and IgM-lambda. The molecules are then measured in pairs (e.g., IgG-kappa / IgG-lambda) to calculate ratios of involved monoclonal immunoglobulin to background uninvolved immunoglobulin concentrations. The tests can be used to monitor people with multiple myeloma.
  • Bone marrow aspiration and biopsy. 
Multiple myeloma is a disease of the bone marrow. People usually require a bone marrow evaluation to confirm the diagnosis, evaluate how many malignant plasma cells are present in the marrow, and determine to what degree they have affected the production of normal white blood cells, red blood cells, and platelets.
  • Cytogenetic analysis. In these tests, which include karyotyping and florescence in situ hybridization (FISH), cells are examined under a microscope to look for abnormal chromosomes. Abnormalities like chromosome translocations (mismatched parts) or deletions are sometimes associated with multiple myeloma. Finding these abnormalities can provide information about an individual's prognosis.

Other laboratory tests
Other tests that may be done as part of an initial diagnostic workup, to monitor the progress of the disease, and to help detect and address complications include:

  • Comprehensive metabolic panel (CMP), a group of tests used to evaluate kidney and other organ function, electrolyte status, and to determine calcium, albumin, and total protein levels
  • Complete blood count (CBC), counts and evaluates white blood cells, red blood cells, and platelets and determines the extent of anemia (measures hemoglobin)
  • Uric acid levels may be elevated as a complication of multiple myeloma.
  • Beta-2 microglobulin, a protein on the cell surface of myeloma and other cells; increased levels may indicate a poorer prognosis; this test may be used to help stage the disease.
  • Serum viscosity, a measure of how "thick" the fluid portion of the blood is; when levels of the abnormal protein become very high, serum viscosity may increase and cause symptoms.

Non-laboratory tests

  • X-ray, ordered to help diagnose, stage, and monitor; may detect holes in bones, extent of bone damage, and the number and size of tumors in the bones.
  • MRI (magnetic resonance imaging), may be more sensitive than X-ray for evaluating bone destruction.
  • CT (computed tomography)/PET (positron emission tomography), may be used to look for bone tumors when an x-ray result is negative but an individual still has bone pain.

Staging helps to determine a person's prognosis and allows the person and their healthcare practitioner to develop an individualized monitoring and treatment plan. Staging evaluates the:

  • Amount of abnormal immunoglobulin being produced
  • Amount of calcium in the blood
  • Degree and severity of bone damage
  • Extent of anemia

There are different staging systems available to assess the amount of tumor tissue present (tumor burden) and organ dysfunction. Some test results, such as blood levels of beta-2 microglobulin and albumin, are especially important in myeloma staging.

« Prev | Next »